Get started
Author

T. Talbot

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).
2007 · Rebecca M. Ricklis, Judith E. Karp, et al. · Blood · 5
119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)
2022 · C. Gessner, F. Griesinger, et al. · Immuno-Oncology Technology · 3
Response adapted de-escalation of neo-adjuvant therapy for intermediate risk HER2-positive early breast cancer: an institutional experience
2024 · T. Talbot, F. Rehman, et al. · Clinical Oncology
PDF
201P Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis
2024 · M.I. Gomez-Randulfe Rodriguez, C. Escriu, et al. · ESMO Open
142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom
2022 · K. Franks, M. Ahmed, et al. · Immuno-Oncology Technology
87: Resource use associated with the management of docetaxel-related haematological toxicities, including neutropenic sepsis (NS), in patients with advanced non-small cell lung cancer (NSCLC) in the UK NHS: REVEAL-NS
2017 · T. Talbot, A. Dangoor, et al. · Lung Cancer
86: The rate of neutropenic sepsis (NS) and other haematological toxicities in patients with advanced non-small cell lung cancer (NSCLC) treated with docetaxel in the UK NHS: REVEAL-NS
2017 · T. Talbot, A. Dangoor, et al. · Lung Cancer
PDF
Works count: 7
Citation count: 8
H-index: 2
I10-index:
Year
Topic
Type